Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hip Infiltration in Hip Arthroplasty (HiHa) randomized controlled trial
2023-509109-57-01Phase 4Authorised
- Sponsor
- Reinier Haga Orthopedisch Centrum
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hip osteoarthritis comparing Ropivacaine hip infiltration with Placebo/control hip injection (2 arms). Primary endpoint: Use of escape pain medication during the first 6 hours after intra-articular hip injection. Planned start Apr 2025; status: authorised.
02
Drugs
ropivacaine
03
Conditions
hip osteoarthritis
Beyond the preview
Go deeper on 2023-509109-57-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509109-57-01.